Clinical trial · Observational
Temporal Diffusion Spectroscopy MRI in Predicting the CPS of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy
Temporal Diffusion Spectroscopy MRI in Predicting the Comprehensive Positive Score of PD-L1 Expression and the Efficacy of Neoadjuvant Therapy in Head and Neck Squamous Cell Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to explore the application of temporal diffusion spectroscopy MRI in head and neck squamous cell carcinoma (HNSCC). The main questions it aims to answer are: * If the quantitative parameters of temporal diffusion spectroscopy MRI can predict the comprehensive positive score (CPS) of pathological PD-L1 expression in HNSCC? * If the quantitative parameters of temporal diffusion spectroscopy MRI can predict the efficacy of neoadjuvant therapy in HNSCC? Participants will receive head and neck MRI, including T2WI, T1WI, diffusion-weighted imaging (DWI), oscillating gradient spin echo (OGSE) and pulsed gradient spin echo (PGSE) sequence before and after neoadjuvant therapy. There is not a comparison group in our study.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
| Magnetic Resonance Imaging | — | UNRESOLVED | — |
| Neoadjuvant Therapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Comprehensive positive score
- timeFrame
- 1 week before neoadjuvant therapy
- description
- Comprehensive positive score for PD-L1 expression
- measure
- Pathological response
- timeFrame
- 1 month after the last neoadjuvant therapy
- description
- Postoperative pathological tumor residual status
- measure
- Change from maximum transverse tumor diameter after neoadjuvant therapy
- timeFrame
- 1 week before the first neoadjuvant therapy and 1 month after the last neoadjuvant therapy
- description
- Maximum transverse tumor diameter before and after neoadjuvant therapy
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients first diagnosed with head and neck squamous cell carcinoma (HNSCC) by pathological biopsy * Patients proposed to receive 2-3 courses of neoadjuvant chemotherapy and immunotherapy * Patients without contraindications for MRI, such as nonremovable ferromagnetic metal foreign body, claustrophobia, renal insufficiency, and previous history of gadolinium contrast allergy Exclusion Criteria: * Less than 10mm in the maximum diameter of the baseline primary tumor * Poor MRI image quality with obvious metal or motion artifacts * The failure to complete the course of neoadjuvant therapy
References
Publications (0)
Data not yet available